Business strategy
Alejandro Schmieder, MBA
Stanford University
Supports venture strategy, company positioning, investor-facing materials, partnership planning, and the business roadmap for the Evolvia BioPharma model.
The team
Builders, scientists, strategists, and advisors advancing a new BioPharma model.
Evolvia BioPharma brings together scientific leadership, business strategy, execution support, and industry advisory experience to build an AI-enabled, partnership-driven drug discovery company.
Core team
Team members
The team combines principal-investigator leadership, business strategy, operations, AI development, and execution support across science, partnerships, and company development.
Strategy & operations
Mohan Raval, MBA
University of Chicago
Supports market analysis, operational planning, business development preparation, and execution systems for outsourced discovery and development programs.
Execution leadership
Christopher Schweitzer, EL
Program execution
Supports program coordination, execution planning, external workflow management, and the operating discipline needed to move discovery concepts toward validation.
Principal Investigator
Karim Ullah, PhD — PI
Scientific vision & portfolio
Leads the scientific vision, therapeutic portfolio direction, company architecture, AI/deep biology strategy, and partner-driven execution model.
AI development team
Aarnav Jain
AI development
Supports AI development, technical prototyping, data workflows, automation, and platform-building work for the Evolvia BioPharma discovery model.
Scientific advisors
Advisory support
Scientific, clinical, and industry advisors strengthen the company’s technical judgment, translational thinking, precision oncology perspective, and BioPharma execution discipline.
Scientific advisor
David Johnson, MBA
Engineer at UChicago
Advises on technical execution, engineering-minded program planning, translational infrastructure, and practical systems for outsourced BioPharma development.
Scientific advisor
Emily Berghoff, PhD
Former Manager at Amgen
Advises on industry-grade program assessment, drug development strategy, scientific prioritization, and the expectations of professional BioPharma execution.
Clinical & scientific advisor
Muhammad Rafiqul Islam, M.B.B.S, MD, MsPH, FACP
Assistant Professor & Clinical Researcher · Precision Oncology
Provides clinical oncology, health data science, precision oncology, and translational medicine perspective for cancer-focused discovery and development strategy.
LinkedIn profileHow the team works
Evolvia BioPharma is built as a lean, AI-enabled, externally partnered company. The internal team focuses on target strategy, scientific decision-making, business development, investor readiness, IP planning, and partner orchestration.
Scientific & AI direction
Therapeutic priorities, target rationale, molecular design logic, AI development, validation planning, and portfolio decisions are led through a PI-driven scientific framework.
Business execution
Strategy, operations, partnerships, and financing materials are developed to support a credible path from discovery concept to validated program.
Advisor-guided development
Advisors provide perspective on technical feasibility, industry standards, development risk, and the operating systems needed for BioPharma execution.
Ownership architecture
Ownership is earned. The company evolves with its builders. Evolvia BioPharma does not assign permanent ownership based only on titles, attendance, or early participation.
10% founder ownership
Permanently locked for the original scientific vision, company architecture, foundational development, and creation of the Evolvia BioPharma model.
90% open ownership
Exactly 90% remains open for scientists, AI researchers, clinicians, drug developers, operators, investors, and partners who create verified value.
Governance follows ownership
Voting power and governance influence emerge from actual earned ownership and demonstrated responsibility.
Open builder network
The company remains open to contributors who can create verified scientific, technical, operational, legal, financial, or strategic value.
Science & discovery
Target rationale, molecular design, medicinal chemistry, validation strategy, and data interpretation.
Execution & partnerships
CRO relationships, experimental logistics, BD relationships, and strategic collaborations.
Capital, IP & growth
Fundraising, investor strategy, legal structure, patent protection, freedom-to-operate support, marketing, and ecosystem development.
Interested in building with Evolvia?
Builders can apply to contribute scientific, technical, operational, legal, financial, and strategic value.